# Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

> **NCT06375707** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 144 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS
- **DRUG:** Ribociclib combined with NSAI±OFS

## Key facts

- **NCT ID:** NCT06375707
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-09
- **Primary completion:** 2025-11
- **Final completion:** 2025-12
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375707, "Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06375707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*